
THE VANGUARD SCIENTIFIC LIBRARY

Three Receptors, One Metabolic Question

GLP-1 / GIP / GLUCAGON

How three hormonal pathways changed the scientific conversation about appetite, glucose regulation, energy expenditure and body weight.



Conceptual pathways; relative receptor contribution differs by molecule and context.

An illustrated narrative review of experimental biology, original animal studies, randomized human trials, competing interpretations and the questions that remain unanswered.

Vanguard Compound Research | Evidence search current to 26 October 2026. Educational scientific synthesis, not peer-reviewed. Not an evaluation of any product, formulation, batch or supplier. No dosing or administration guidance. Not reviewed or approved by Health Canada.

THE QUICK READ

What makes this research important?

A hormone that reduces appetite is interesting. Two hormones that influence appetite and insulin signaling are more interesting still. But a third pathway adds an apparent contradiction: glucagon can support energy expenditure, yet it can also tell the liver to release glucose. The challenge is to combine signals without allowing one desired effect to overwhelm another. [1-5]

WHAT SCIENCE SUPPORTS	WHAT IT DOES NOT YET ESTABLISH
Human metabolic outcomes can change markedly in **specific randomized trials** of particular triple-receptor candidates. [6-9]	That every molecule with the same three receptor labels performs identically, or that a research product matches trial material.
Rodent experiments support a mechanistic role for glucagon-receptor signaling in certain experimental energy-expenditure effects. [1-3]	That the same fraction of human weight reduction necessarily arises from higher energy expenditure.
Published trials provide meaningful short- and medium-term data on weight and, in diabetes, HbA1c. [6-9]	Decades-long safety, universal responses, or a permanent result after treatment is stopped.

> The exciting result is **not** that all three receptors produce a predictable super-effect. It is that carefully engineered multi-receptor signals have now shown measurable human outcomes - while leaving major mechanistic and long-term questions open.
>
> READING THE EVIDENCE

This paper follows that sequence: the hormones; the biological paradox; the original rodent experiments; the evolution to controlled human trials; observed efficacy; observed harms; and the limits of any commercial or personal interpretation. Numerical trial findings are always attributed to the particular publication from which they came.




FIGURE 01. Milestones in the published development of dual- and triple-receptor metabolic research. Dates refer to studies cited in the reference library, not regulatory milestones.

CHAPTER 01 / THE SCIENTIFIC STORY

The conversation inside metabolism

Before considering one molecule that activates three receptors, it helps to hear the three hormonal voices separately.

The endocrine system does not regulate body weight through a single dial. It responds to absorbed nutrients, circulating fuel, energy reserves, time since the last meal and signals traveling from the gut to the brain. GLP-1, GIP and glucagon participate in this network, but they are neither interchangeable nor limited to a single organ. [1-5]

GLP-1: connecting food intake to satiety and insulin

Glucagon-like peptide-1 is secreted from intestinal enteroendocrine cells following nutrient exposure. Through its receptor, GLP-1 can augment glucose-dependent insulin secretion, influence glucagon responses to elevated glucose, slow gastric emptying under some conditions and engage central and peripheral pathways related to satiety. These individual effects are not necessarily equally important for every long-acting pharmacological agonist. The modern clinical interest in GLP-1 signaling emerges from the combination of glucose regulation and the ability to change eating behavior. [5,6]

An important distinction is that appetite suppression is a human outcome mediated by complex circuitry, not a direct measurement of a particular hypothalamic neuron firing. A person eating less in a clinical trial does not prove a simple central nervous system mechanism, and receptor expression alone does not prove a clinical benefit.

GIP: a nutrient signal whose pharmacology surprised researchers

Glucose-dependent insulinotropic polypeptide is produced by intestinal K cells and is another important incretin. It can enhance insulin secretion when glucose is elevated. GIP biology also involves adipose tissue, glucagon secretion under some glycemic conditions and central signaling. Its metabolic actions have long seemed context-dependent; the effects of stimulating or blocking GIP receptors in experimental models cannot be summarized as a universal rule that one direction must always promote weight loss. [4,5]

That complexity is precisely why combined receptor pharmacology matters. When GIP receptor activation is paired with GLP-1 receptor activation, responses can reflect interactions among insulin secretion, appetite, tolerability, and systemic metabolism rather than three isolated switches being turned on at once. One cannot infer the performance of a triple-receptor molecule from its GIP binding affinity alone.

Glucagon: the hormone that made the proposition daring

Glucagon, released mainly from pancreatic alpha cells, is classically associated with increasing hepatic glucose production, especially when circulating glucose threatens to fall. That makes it seem an unlikely partner in a glucose-lowering therapeutic strategy. Yet glucagon signaling can also affect hepatic substrate turnover, amino-acid metabolism, lipid metabolism and energy expenditure under certain experimental conditions. [2,3,5]

This tension gives the triple-receptor concept its central scientific question: can favorable effects on energy balance coexist with adequate glucose control? Early chemistry and animal experiments suggested that appropriately designed co-agonism could do so in rodents. Human clinical trials were needed to determine whether the principle translated. [1-3]




FIGURE 02. Simplified organ map. Receptor-mediated effects differ by tissue, dose exposure, species, study design and the molecule being tested; arrows are intentionally omitted to avoid implying unproven causal magnitudes.

CHAPTER 02 / THE SCIENTIFIC STORY

The glucagon paradox

Why researchers deliberately explored a receptor usually associated with raising blood glucose.

Imagine a signal that increases the release of stored glucose from the liver. On its own, that could work against glucose control in type 2 diabetes. Now imagine combining it with signals that alter nutrient intake, insulin secretion and the timing of carbohydrate appearance in the circulation. The result might be very different from any one hormone alone. That is the appeal of receptor co-agonism. But this is a design hypothesis, not a mathematical guarantee. [1-5]

In 2009, two influential rodent research programs compared GLP-1/glucagon dual-receptor compounds with appropriately selected comparators. Day and colleagues studied co-agonists with differing glucagon activity and described fat-mass reduction associated with reduced food intake and increased energy expenditure. Pocai and colleagues used matched GLP-1 receptor potency as part of their comparison, reporting additional metabolic effects from glucagon receptor engagement in diet-induced obese mice. These studies mattered because they aimed to isolate something about the second receptor rather than merely demonstrate that any active peptide reduced weight. [1,2]




FIGURE 03. The glucagon paradox as a design problem. The left- and right-hand effects are plausible biological routes; the balance depicted is conceptual and is not a quantitative model of human glucose or caloric balance.

The temptation is to translate the animal finding into the assertion that human triple agonists melt fat by substantially increasing the resting metabolic rate. The literature supports a narrower statement. Human experiments with glucagon infusion have detected acute increases in energy expenditure, but these studies were small and did not establish the chronic contribution of that mechanism to the weight loss seen with a long-acting triple-receptor investigational drug. One human study even found an energy-expenditure response that did not track with the measured activation of brown adipose tissue. [4]

> Glucagon receptor activity is a **scientific reason to investigate energy expenditure**. It is not proof that observed weight reduction in any specific clinical trial was caused primarily by burning more calories.
>
> READING THE EVIDENCE

The more persuasive science therefore combines several measures: energy-intake behavior, glucose concentration, HbA1c, body composition, indirect calorimetry, hepatic substrate flux and tolerability. Each tells a different part of the story. A reduction in scale weight alone does not identify the underlying distribution of mechanisms.

CHAPTER 03 / THE SCIENTIFIC STORY

The experiment that united all three

Rodent models showed that a single designed molecule could engage GLP-1, GIP and glucagon receptors and produce substantial whole-animal effects.

The 2015 Nature Medicine paper by Finan and colleagues was a major turning point. Its team described a monomeric molecule intentionally designed with activity at all three receptors. In rodent models of diet-induced obesity and disturbed glucose metabolism, the investigators reported reductions in body weight and improvements in metabolic measures. Additional mechanistic comparisons and genetically modified models helped explore how the receptor components contributed to observed effects. [3]

Why was this more than a clever chemistry exercise? Earlier dual-agonist work had asked whether activating GLP-1 and glucagon receptors together could outperform a narrower signal in rodents. Bringing GIP into the design raised a deeper question: might three partially complementary pathways yield a better organism-level balance, including appetite and glucose handling, than either a single or dual pathway in specific settings? The experiments provided a reason to take that question into human studies. [1-3]

The strength of the animal evidence comes partly from experimental controls unavailable in ordinary human treatment. Researchers can choose genetically defined animals, tightly regulate food conditions, monitor body composition and compare receptor pathway disruptions. But this very control also limits external validity. Laboratory rodents are not a miniature substitute for adults with long-duration obesity, type 2 diabetes, cardiovascular disease, diverse medication histories and different social and nutritional environments.

What the animal work did - and did not - establish

DESIGN FEATURE	SCIENTIFIC VALUE	LIMITATION
Designed three-receptor activity	Tests feasibility of a multi-pathway signal	Receptor activity may differ across species and compounds
Diet-induced obesity models	Allows controlled comparisons of body weight and metabolic outcomes	Does not replicate the heterogeneity of human obesity
Mechanistic receptor comparisons	Strengthens causal arguments about specific pathways	Cannot establish long-term human safety or effectiveness

One of the most instructive points is that “triple agonist” is a category of receptor engagement, not a chemical identity. Two molecules can bind GLP-1, GIP and glucagon receptors and differ substantially in relative potency, pharmacokinetics, tissue exposure, receptor selectivity, off-target actions and tolerability. The useful animal finding was that the strategy could work in a model. The question of which designs work best in humans remained open.

CHAPTER 04 / THE SCIENTIFIC STORY

Crossing the species boundary

Carefully controlled clinical studies moved the question from receptor theory to measured human outcomes.

The early human development sequence placed safety, exposure and pharmacodynamic changes under structured observation. A 2022 randomized phase 1b investigation in adults with type 2 diabetes examined a specific investigational triple-receptor agonist and helped establish that simultaneous pathway activation could be studied under clinical-trial conditions. This was not yet a definitive obesity outcome trial. It was a bridge from animal plausibility to questions of human tolerability and metabolic effects. [5]

Larger phase 2 investigations then asked something more concrete: compared with control groups, how much did body weight or HbA1c change over a specified period? That change in endpoint matters. Receptor engagement is an important laboratory property, but clinical research succeeds or fails on outcomes people actually experience, alongside burdens they are exposed to in the process. [6,7]




FIGURE 04. Development sequence: two-pathway animal demonstrations, three-pathway rodent experiments, then staged controlled human trials. Study years are sourced to references [1-9].

Even a successful randomized trial answers a limited question. It estimates the effect of the studied pharmaceutical preparation, at that trial's exposure schedule and among its selected participants, over the reported follow-up. It does not establish that a separately sourced research vial contains an equivalent pharmaceutical ingredient, is sterile, has the same purity profile or carries the same risk-benefit properties.

Why randomized design matters

Body weight and glucose can shift for many reasons: dietary change, background treatment, study contact, regression toward the mean, adherence, illness or stopping another medicine. Random assignment and blinded control groups help separate the effect of a tested intervention from this surrounding noise. Completion rates, missing data and the statistical estimand still matter. A result reported among people who remained on treatment is not automatically the same as a treatment-policy estimate including discontinuation. [6-9]

CHAPTER 05 / THE SCIENTIFIC STORY

The first striking human weight signals

A 2023 phase 2 obesity trial showed why three-receptor pharmacology drew so much attention - and why the details of a trial matter.

Jastreboff and colleagues enrolled 338 adults with obesity or overweight plus a weight-related condition into a randomized, double-blind, placebo-controlled trial. At 48 weeks, the mean body-weight reductions in the trial's active groups ranged from 8.7% to 24.2%, depending on the assigned investigational regimen; the corresponding placebo group mean was 2.1%. This was a substantial signal in that particular candidate and trial, not an expected response for an entire biochemical class. [6]

The trial design included multiple active arms and starting conditions. Reporting only the largest percentage would obscure that the observed effects varied across arms, and also that participants were selected using eligibility criteria. The most informative scientific reading recognizes both the size of the largest mean change and the variation, duration, comparators and missing long-term information. [6]

There was a tolerability story alongside the efficacy story. Gastrointestinal adverse events were the most common, were related to exposure in that study and were usually described as mild to moderate. Heart-rate increases were also observed, peaking around the middle of the study and declining afterward. Those are genuine elements of the published evidence; describing weight reduction without them would distort the trial's meaning. [6]

> One headline number can be memorable. The clinically important evidence is the **whole randomized experiment**: who was studied, what was compared, how outcomes were measured and what harms accompanied the changes.
>
> READING THE EVIDENCE

The larger unanswered mechanistic question remained: how much of the observed weight change came from eating less, altered nutrient processing, higher energy expenditure, or other adaptations? A trial demonstrating weight loss is not automatically an experiment proving the proportional contribution of each receptor. To answer that, investigators need specifically designed mechanistic work and appropriate comparators.

CHAPTER 06 / THE SCIENTIFIC STORY

A second test: glucose control

In people with type 2 diabetes, a 2023 randomized phase 2 study measured HbA1c and weight, revealing benefits and limitations at the same time.

Rosenstock and colleagues studied 281 randomized participants with type 2 diabetes in a placebo- and active-controlled phase 2 trial. The primary endpoint was HbA1c change at 24 weeks, with additional outcomes including body weight at 36 weeks. In the most intensive investigational arm, mean HbA1c changed by about -2.02 percentage points at week 24; in the placebo arm, it changed by about -0.01 points. These values refer to one study and its specific trial regimen, not to all triple-receptor compounds. [7]

The same study reported weight reduction across active arms, with an upper reported mean reduction of roughly 16.94% at 36 weeks, versus about 3.00% in the placebo arm. The active comparator was useful because it added context beyond the comparison with no active pharmacological intervention. The controlled design strengthens causal interpretation of these particular study outcomes, while the moderate sample size and duration still limit conclusions about rare events and long-term durability. [7]

It is worth pausing on why the HbA1c result is biologically interesting. The traditional account of glucagon emphasizes glucose production, yet this three-receptor experimental strategy improved an integrated measure of average glycemia over several months. That observation supports the possibility that net system-level glucose balance can be favorable despite activity at a receptor with glucose-raising potential. It does not prove that glucagon activation independently improved glycemia. [3,7]

Tolerability is part of the result

In that phase 2 diabetes study, mild-to-moderate gastrointestinal events occurred in about 35% of participants pooled across the investigational active groups, with meaningful variation among individual groups, compared with about 13% in placebo. No severe hypoglycemia and no deaths were reported during the study. Those observations are reassuring within the trial, but a few hundred people followed for months cannot exclude uncommon or delayed adverse outcomes. [7]

MEASURE	OBSERVATION IN THE 2023 DIABETES TRIAL	HOW TO READ IT
HbA1c at 24 weeks	Up to about 2.02 percentage points mean decrease in an active arm; placebo approximately unchanged	Study-arm result, not a class guarantee
Body weight at 36 weeks	Upper observed active-arm mean decrease near 16.94%; placebo near 3.00%	Endpoints and timing differ from the HbA1c result
Gastrointestinal events	Reported across active groups; frequency varied by arm	Benefit and burden must be interpreted together

CHAPTER 07 / THE SCIENTIFIC STORY

From promising trials to a wider evidence base

By 2026, larger studies and more than one investigational molecular design had become part of the story.

The distinction between a scientific platform and a specific molecule became more important as the literature expanded. Bellido and colleagues published a phase 3 trial in adults with obesity and type 2 diabetes, enrolling 1,152 people at 92 centers across eight countries. At 80 weeks, mean body-weight changes in three active arms were -11.9%, -16.8% and -18.8%, compared with -5.1% for placebo under the treatment-regimen estimand. These are large-study data from one pharmaceutical candidate, not a generic efficacy range for every receptor triple agonist. [8]

The trial extended the observation period and broadened the study population beyond the earlier phase 2 experiments. That improves the evidence for the specific candidate studied, but it also makes the details of the estimand and withdrawals more significant. Researchers report a mean treatment effect across a population under defined assumptions; an individual’s response can be substantially smaller, larger or limited by adverse events or discontinuation. [8]




FIGURE 05. Study-specific randomized mean weight outcomes in adults with obesity and type 2 diabetes at 80 weeks. The four bars are treatment arms from Bellido et al. (2026), not receptor effects or predictions for another preparation. [8]

The less appealing findings should remain in the same paragraph as the weight outcomes. Gastrointestinal symptoms were more frequent in the active groups, and the published report also identified higher occurrence of certain events, including dysesthesia and hypotension, than in

placebo. A trial can demonstrate a meaningful average benefit while some participants experience significant tolerability problems. Both observations are part of the science. [8]

Evidence from a different investigational candidate

A separate multicenter, double-blind, placebo-controlled phase 2 study led by Zhou, published in 2026, tested another triple-receptor molecular design in 205 adults with overweight or obesity without type 2 diabetes. Over 24 weeks, the published mean changes in body weight among active groups ranged from about -13.6% to -19.7%, compared with approximately -2.0% on placebo. Gastrointestinal events remained the most frequently reported adverse events. This second candidate helps show that the approach is an active field rather than a single development program. [9]

But putting those numbers side by side is not a head-to-head comparison. The participants, study duration, molecules, receptor potency balance, titration methods, sites, endpoints and statistical handling differ. A 24-week range from one study and an 80-week result from another cannot rank the substances. An actual comparative randomized study would be needed to answer that question. [8,9]

> Two successful-looking studies using different molecules strengthen interest in **triple-receptor biology**. They do not make the chemistry of those molecules equivalent or permit clinical ranking across unrelated trials.
>
> READING THE EVIDENCE

Also published in 2026 was an 80-week randomized phase 3 investigation involving 2,339 adults with obesity without diabetes. Reported mean body-weight changes across its active groups ranged from -17.6% to -25.0%, versus -3.9% for placebo. The trial also evaluated pain in a subgroup with knee osteoarthritis and sleep-apnea events in a subgroup with obstructive sleep apnea, reporting improvements in specified comparisons. Those additional endpoints expand clinical interest but should be interpreted within their prespecified populations and analysis rules; they are not promises of disease reversal for other people or other molecules. The longer observation window also cannot resolve effects after discontinuation or very rare late harms. [10]

CHAPTER 08 / THE SCIENTIFIC STORY

What is actually making the weight change?

The mechanism is likely richer than a simple “eat less plus burn more” equation, and the proportions remain uncertain.

The first mechanism is intuitive: changes in satiety and reward-related eating can reduce caloric intake, often without deliberate counting. GLP-1 receptor signaling is relevant here, while GIP receptor engagement may alter some aspects of the response under combination pharmacology. But hunger, meal size and food preference are behavioral outcomes influenced by more than receptor occupancy. Laboratory measures, real-world intake and subjective appetite do not always align perfectly. [5-9]

The second possible mechanism is energy expenditure. In rodent studies, glucagon receptor activity contributed to selected increases in expenditure and reductions in fat mass. A small human infusion study detected acute increases in energy expenditure from glucagon, but these observations cannot be converted into a fixed number of calories burned every day by a chronic triple-receptor therapy. Dose-exposure patterns, physiological compensation and species differences may all alter the magnitude. [1-4]

A third layer is fuel handling. The liver can alter glucose output, amino-acid turnover and aspects of lipid metabolism under glucagon signaling. The pancreas responds to glucose and incretin signaling; insulin and glucagon act in a feedback system, not as isolated drug targets. Meanwhile, changes in adipose tissue mass alter the endocrine environment over time. Metabolic outcomes reflect those shifting conditions. [2-5]

Weight loss is not a single tissue measurement

A change on the scale combines fat, lean tissue, water, gastrointestinal contents and, over long periods, structural adaptation. Clinical research increasingly needs to ask what happens to muscle mass and strength, cardiometabolic risk factors, liver fat, nutritional status and day-to-day function. A major decrease in total body weight is an important measurable outcome; body-composition measurement and functional endpoints help establish whether the overall change is desirable and sustainable for different people.

This matters especially for interpreting animal results. When animals lose predominantly fat mass in a tightly controlled experiment, it does not establish the precise fat-to-lean ratio in older adults, people with baseline sarcopenia or patients with several chronic conditions. The most useful future

human studies will pair weight outcomes with serial body-composition measurements, adequate nutritional monitoring and meaningful physical-function assessments.

Could the receptors interact in unexpected ways?

Yes. The amount of receptor activation is not a simple on/off state; potency at each receptor, signaling bias, tissue distribution, desensitization and the profile of circulating drug can all matter. Glucose-dependent insulin secretion under GIP and GLP-1 signaling may offset glucose-raising tendencies of glucagon in some conditions, but that balance changes with baseline pancreatic function, eating state, concurrent medication and time. Therefore receptor affinity measured in a cellular assay is not enough to predict a whole-person clinical result. [3,5-9]

An especially instructive research strategy is to compare mechanistically matched molecules that differ in a single receptor property, as the early dual-agonist teams attempted. Observations from such studies can reveal causality that simple comparisons of unrelated triple agonists cannot. The ultimate objective is not simply three targets on a label but an understood and reproducible physiological response. [1-3]

CHAPTER 09 / THE SCIENTIFIC STORY

What the evidence says about safety

An intellectually honest review keeps adverse events next to efficacy, not in fine print at the end.

Gastrointestinal events have appeared prominently in published human trials of triple-receptor candidates. The studies describe nausea, diarrhea, vomiting and constipation, with severity and frequency varying by study arm and exposure schedule. Some participants discontinued treatment because of adverse events. The fact that many events were reported as mild or moderate does not make them irrelevant: persistent symptoms can affect food intake, hydration, nutrition and the ability to remain in a trial. [6-9]

The 2023 obesity trial observed increases in heart rate, with a time course that changed during follow-up. The 2026 phase 3 diabetes/obesity trial reported additional adverse-event differences, including dysesthesia and hypotension, between study arms. Investigators and regulators must consider such observations in relation to mechanism, baseline risk, duration of exposure and possible interactions with other therapy. [6,8]

WHAT THE TRIALS OBSERVED	WHAT THIS MEANS	WHAT IS STILL UNKNOWN
Gastrointestinal events were common in active groups. [6-9]	Tolerability is an important component of net benefit.	Exact risk for a different molecule or untested formulation.

WHAT THE TRIALS OBSERVED	WHAT THIS MEANS	WHAT IS STILL UNKNOWN
Heart-rate changes were reported in one phase 2 obesity trial. [6]	Monitoring signals deserve mechanistic analysis.	Consequences of years of continuous exposure.
Some adverse-event categories increased in the 2026 phase 3 trial. [8]	Larger studies detect additional safety patterns.	Very rare or delayed events beyond available follow-up.
No severe hypoglycemia was reported in one limited diabetes phase 2 sample. [7]	A useful trial observation.	Risk in different patients, contexts or concurrent therapies.

Interpretation becomes more complicated in people taking other glucose-lowering medicines. A clinical trial can use carefully defined inclusion criteria and medication rules; those safeguards do not automatically exist outside the trial. Particular caution is needed before extrapolating results to pregnancy, pediatric populations, frail older adults, people with advanced organ disease or people with complex polypharmacy when those groups were not adequately represented.

The absence of a severe event in a study of a few hundred participants is not strong evidence that the event cannot occur. Detection of a rare risk may require much larger exposures and longer observation. Conversely, suspected class risks should not be presented as if they were conclusively demonstrated for every triple-receptor molecule. Scientific caution cuts in both directions: avoid false reassurance and avoid unsupported certainty about harm.

> A statistically impressive weight curve does not convert an experimental injectable into a finished, authorized medicine. Identity, potency, sterility, impurities, stability and manufacturing quality are separate scientific and regulatory questions.
>
> **READING THE EVIDENCE**

CHAPTER 10 / THE SCIENTIFIC STORY

Human applications: promise and boundaries

The strongest discussion of possible application begins with what has been studied, then asks exactly how far those data can travel.

The broad research goal is understandable. Obesity is associated with cardiometabolic risk; type 2 diabetes involves impaired glucose regulation; and many affected people face multiple interacting challenges around energy balance. An experimental approach that changes appetite, weight and glycemia is worthy of serious investigation. The controlled human data discussed in this review support further study of such approaches. They do not support a general promise that any three-receptor compound will produce a stated percentage of weight loss, improve all comorbidities or be suitable for unsupervised use. [6-10]

What could future well-designed research clarify?

First, receptor contribution. Do people benefit from glucagon receptor agonism above the effect of optimized GLP-1 and GIP activation, and in which metabolic phenotypes? Second, durability. What happens to weight and HbA1c after several years and after treatment ends? Third, composition and function. How much of the changing weight is fat versus lean tissue, and what are the consequences for physical performance? Fourth, outcomes beyond surrogate markers. Do particular agents alter major cardiovascular, renal, liver or mortality endpoints in adequately powered trials?

Fifth, tolerability and individual differences. Are different molecular balances associated with meaningfully different gastrointestinal, cardiovascular, sensory or nutritional burdens? What determines people who respond strongly versus modestly? Finally, comparative science. Directly randomized studies are necessary before one investigational design can credibly be called superior to another. Each of these questions may lead to important future experiments, regardless of how a particular commercial development program proceeds.




FIGURE 06. Evidence hierarchy for this topic. Human outcome studies are essential, but long-term risk-benefit questions remain a separate higher-order layer of evidence.

A note on published human findings and research materials

The human trials cited here used defined pharmaceutical investigational materials produced and studied under clinical protocols. Their findings do not validate products sold separately under a research designation. Analytical confirmation of molecular identity and content is not a substitute for clinical safety, sterile-manufacturing assurance, biological equivalence or regulatory authorization. A certificate of analysis is not a clinical-trial bridge from one source to another.

In Canada, whether a publication forms part of advertising depends in part on context, not merely on the presence of a disclaimer. Health Canada distinguishes informational activity from promotion by evaluating such factors as content, intended audience, placement and commercial links. This research review therefore avoids clinical use instructions, specified dosing, personal testimonials and marketing claims. Its neutral format and disclaimers should not be construed as a legal conclusion that commercial use of it is compliant. [11]

CHAPTER 11 / THE SCIENTIFIC STORY

The frontier - and the honest conclusion

The most exciting part of three-receptor science may be how much measurable biology has emerged from an idea that once sounded contradictory.

The idea started with a provocative observation: stimulating glucagon signaling might alter how the body spends energy, although glucagon also promotes hepatic glucose release. Early dual-agonist studies in mice suggested that receptor combinations could change the overall physiological outcome. A 2015 rodent triple-agonist experiment strengthened the concept by testing all three hormone-receptor pathways in one designed molecule. Human studies then moved the conversation from a plausible mechanism to randomized observations of body weight, glycemia and adverse events. [1-9]

The 2023 and 2026 trial reports are noteworthy because several yielded substantial mean changes under controlled conditions. The existence of another 2026 phase 2 candidate also makes clear that three-receptor signaling is a pharmacological research strategy, not a synonym for one investigational chemical entity. Yet dramatic means do not guarantee dramatic individual results, do not prove a single mechanism, and do not remove the burden of defining safety over longer periods. [6-10]

> The real breakthrough is the **quality of the question science can now ask**: how can GLP-1, GIP and glucagon signals be tuned into a clinically useful balance - and how can that balance be demonstrated rigorously in humans?
>
> THE CENTRAL TAKEAWAY

For the reader, the fairest conclusion is neither cynicism nor enthusiasm without qualification. The field contains strong mechanistic experiments and increasingly serious human outcome research. At the same time, the medical significance of any particular candidate depends on its exact chemistry, controlled clinical evidence, adverse-event profile, long-term results and regulatory status. Scientific curiosity is fully compatible with these boundaries.

This review is designed to explain those studies, not to instruct use of an investigational compound or imply that the evidence for trial materials transfers to separately supplied research products.

THE SOURCE LIBRARY

Primary research and regulatory context

Original animal experiments, human trials and a Canadian regulator policy document. References are numbered in order of narrative use. Descriptive annotations are editorial summaries rather than reproduced publication titles. Click the DOI or source address to open the underlying record.

[01] Day JW et al. (2009). Dual GLP-1/glucagon agonism in rodent obesity models. Nature Chemical Biology 5:749-757. 10.1038/nchembio.209

[02] Pocai A et al. (2009). Glucagon-like peptide-1/glucagon receptor dual agonism and obesity in mice. Diabetes 58:2258-2266. PubMed 19602537

[03] Finan B et al. (2015). Rationally designed GLP-1/GIP/glucagon triagonism in rodent models. Nature Medicine 21:27-36. 10.1038/nm.3761

[04] Salem V et al. (2016). Human glucagon infusion, energy expenditure and brown adipose tissue. Diabetes, Obesity and Metabolism. 10.1111/dom.12585

[05] Urva S et al. (2022). Randomized phase 1b clinical investigation of triple-receptor pharmacology in type 2 diabetes. The Lancet 400:1869-1881. 10.1016/S0140-6736(22)02033-5

[06] Jastreboff AM et al. (2023). Randomized phase 2 clinical obesity trial of one investigational triple-receptor candidate. New England Journal of Medicine 389:514-526. 10.1056/NEJMoa2301972

[07] Rosenstock J et al. (2023). Randomized phase 2 trial in adults with type 2 diabetes. The Lancet 402:529-544. 10.1016/S0140-6736(23)01053-X

[08] Bellido V et al. (2026). Randomized phase 3 clinical trial in adults with obesity and type 2 diabetes. The Lancet 408:1455-1472. 10.1016/S0140-6736(26)01861-1

[09] Zhou Z et al. (2026). Randomized phase 2 trial of a separate triple-receptor candidate in adults with overweight or obesity. Cell Metabolism, online ahead of print. 10.1016/j.cmet.2026.09.021

[10] Jastreboff AM et al. (2026). Randomized phase 3 obesity trial, 80-week observation. New England Journal of Medicine, published online September 2026. 10.1056/NEJMoa2604169

[11] Health Canada. Policy on distinction between advertising and other activities, official regulator guidance. Health Canada policy

INTERPRETIVE NOTES

Method: Selected primary research and Canadian policy; not a systematic review or meta-analysis. Results from different trials have not been pooled or ranked.

Scientific integrity: Editorial omission of candidate names does not change the identity of the molecules in the cited trials. DOI links identify each original study; its results cannot be transferred to other research materials.

Scope: Education only; no clinical instructions, dose guidance, product validation or claim of Health Canada authorization. Commercial placement can change the regulatory interpretation of content.